live better, longer
Osteoporosis drugs are used often in the conventional medical model. In some cases, they are overused. In other cases, they are necessary and can be life-changing.
The hard part is knowing which drug makes sense, when it makes sense, and what the long-term plan should be.
One drug that gets a lot of attention is Evenity, also known as romosozumab.
Evenity is powerful. If you look at the clinical trials, it can increase bone mineral density and reduce certain fractures. That is why many physicians are excited about it.
But Evenity also has weaknesses. It has a short window of benefit. It can suppress bone turnover after the initial building phase. And there are ongoing concerns around cardiovascular risk.
So if your doctor is recommending Evenity for you or someone you love, this is a drug worth understanding before you start.
Let’s break it down.
Evenity is a medication used for osteoporosis. Its generic name is romosozumab.
It is called a sclerostin inhibitor.
That sounds complicated, so let’s simplify it.
Sclerostin is a protein made by bone cells. One of its jobs is to slow down bone formation. When you block sclerostin, you remove that brake.
That means Evenity can do two things at once:
This is why Evenity is different from many other osteoporosis drugs.
Bisphosphonates and Prolia mainly work by slowing bone breakdown. Evenity has a dual effect, which is what makes it so powerful in the short term.
On paper, that sounds like exactly what we want.
But no drug is free of tradeoffs.
Evenity was studied in several major clinical trials. The big ones include:
These trials looked at fracture outcomes, bone mineral density changes, and bone turnover markers.
The results are part of why Evenity became such a popular option for osteoporosis treatment.
But when we review drug data, we need to look carefully at the numbers.
Relative risk reduction can sound dramatic. Absolute risk reduction gives a more realistic picture.
Both matter.
One of the most quoted results from Evenity research is that it reduced new vertebral fracture risk by about 73% in the first year in one major trial.
That sounds huge.
And it is meaningful.
But that number is a relative risk reduction.
Relative risk compares one group to another and reports the percentage difference between them. It can make the result sound very large.
Absolute risk reduction tells you the actual difference in event rates between the groups.
For example, if one group has a fracture rate of 2% and the other group has a fracture rate of 0.7%, the relative risk reduction sounds large. But the absolute difference is 1.3%.
That is still useful, especially across a large population. But it feels very different from “73%.”
This matters because patients need to understand the real size of the benefit before accepting the risk.
Evenity appears strongest when it comes to reducing vertebral fractures.
That makes sense because many osteoporosis drugs perform better in the spine than they do at the hip. Spine bone is more metabolically active and often responds more quickly.
In the FRAME trial, Evenity showed a strong reduction in new vertebral fractures during the first year.
That is clinically meaningful.
But we need to ask:
Many vertebral fractures in trials are identified by x-ray screening, not because the person had obvious symptoms. Those fractures still matter, but they are not the same as a painful spine fracture or a hip fracture that leads to hospitalization.
So yes, Evenity is powerful for vertebral fracture outcomes. But the details matter.
The benefit becomes less dramatic when you look at non-vertebral fractures and hip fractures.
That does not mean Evenity does nothing for the hip. It means the effect is not as strong as what we see in the spine.
This is important because hip fractures are one of the most devastating outcomes of osteoporosis.
A hip fracture can lead to:
So when evaluating any osteoporosis drug, we cannot only look at spine bone density. We also need to understand what it does for the hip and for real-world fracture risk.
Evenity can increase bone mineral density.
In some trial data, bone density improvements look very impressive, especially when Evenity is followed by an anti-resorptive medication like Prolia or a bisphosphonate.
But again, we need context.
Some of the reported improvements are compared to placebo. If the placebo group loses bone, the difference between the groups becomes larger.
That does not mean Evenity did not build bone. It did.
But it means the headline number may not represent the exact amount of bone gained by the treated person.
This is why I always want people to ask:
The answer gives a clearer picture.
This is one of the most important pieces of the Evenity conversation.
Evenity initially increases bone formation markers. Specifically, P1NP, a marker of bone building, rises early.
That is the exciting part.
But the rise does not last.
In the trials, P1NP climbs quickly, peaks early, and then starts to fall. Around the six-month mark, it often crosses back toward baseline or below baseline.
At the same time, CTX, a marker of bone breakdown, is suppressed.
So the drug starts as a bone-building tool, but that building effect appears short-lived.
This is one reason Evenity is only used for a limited time.
If Evenity is only strongly anabolic for a short period, then the timing matters.
It may be most useful when someone needs a short-term boost in bone formation because their fracture risk is severe or urgent.
But it is not a forever plan.
It is a short-term tool that must be followed by a clear next step.
After Evenity, patients are usually transitioned to an anti-resorptive medication. This might be a bisphosphonate or Prolia.
The reason is simple:
If you build bone with Evenity and then do nothing, you may lose some of the benefit.
The anti-resorptive helps “hold on” to the gains.
But this creates an important long-term question:
What is the full plan?
If you use Evenity for 12 months, then switch to Prolia, what happens after that? If you switch to a bisphosphonate, how long will you use it? What happens after the drug holiday? What are you doing with nutrition, muscle, hormones, fall risk, and inflammation at the same time?
This is where many conventional plans fall short.
The drug is started, but the long-term strategy is unclear.
The biggest concern with Evenity is cardiovascular risk.
In one of the major trials, there was an increase in serious cardiovascular events in the Evenity group compared to the comparison group.
The difference was not massive, but it was statistically significant.
This led to warnings and restrictions around the drug.
The concern is especially important because many people with osteoporosis are older, and as we age, cardiovascular disease becomes more common.
So the question becomes:
Where do we draw the line?
It is one thing to say, “Do not use this in someone who recently had a heart attack or stroke.”
That makes sense.
But what about someone with plaque? What about high ApoB? What about high blood pressure? What about insulin resistance? What about strong family history?
This is where individualized risk assessment matters.
We should not improve bone at the expense of the heart.
Evenity may be a reasonable tool for certain people.
The best use case is someone who needs a rapid short-term improvement because fracture risk is high.
That might include someone who:
In that population, Evenity may be worth considering.
But it should not be used casually.
It should be part of a full strategy, not the entire strategy.
I would be more cautious with Evenity in people who have higher cardiovascular risk.
That includes people with:
This does not automatically mean every person in these categories can never use it. But it does mean the conversation needs to be careful.
Risk-benefit matters.
If someone is actively fracturing, the risk-benefit calculation may look different. If someone has mild osteopenia and no fracture history, the calculation should look very different.
If Evenity is being recommended, ask these questions:
These questions help move the conversation from “take this drug” to “what is the full plan?”
Evenity can change bone turnover. It can improve bone density. It can reduce some fracture outcomes.
But it does not fix the reasons someone lost bone in the first place.
It does not automatically correct:
This is why drugs and lifestyle should not be framed as enemies.
Sometimes a drug is needed. But the foundation still matters.
A drug may reduce short-term fracture risk. The long-term goal is to build a body that is stronger, more resilient, and less likely to fracture.
Evenity is one of the more powerful osteoporosis drugs available. It works differently than bisphosphonates and Prolia because it can both increase bone building and reduce bone breakdown.
But the benefits are strongest in the short term.
The bone-building marker response appears to peak early and fade within months. The drug is limited to a 12-month course. It usually needs to be followed by another medication. And cardiovascular risk must be taken seriously.
So the right question is not:
Is Evenity good or bad?
The better question is:
Is Evenity the right tool for this person, at this time, with this risk profile, and with this long-term plan?
For some people, the answer may be yes.
For others, especially those without severe fracture risk or with significant cardiovascular risk, the answer may be no.
A diagnosis of osteoporosis is not the end. But deciding to reverse it is the beginning.
This content is for educational purposes only and is not medical advice. Osteoporosis medications, including Evenity/romosozumab, carry potential risks and may not be appropriate for everyone. Do not start, stop, or change medications without speaking with a qualified healthcare professional who understands your medical history, fracture risk, cardiovascular risk, and treatment goals.
Your Blueprint for Lasting Bone Health and Longevity
.svg)
.svg)
.svg)
.svg)
Join us LIVE July 9th, 2026 at 3:00pm EST to Learn Dr. Doug's proven framework for Osteoporosis Reversal for FREE. Yes! Reversing Osteoporosis is possible and has happened for hundreds of Dr. Doug's patients.
If you have been blind-sided, feel stuck, confused, and exhausted with your diagnosis, this Masterclass is for you!
.svg)
.svg)
